Abstract: KPCB China Fund, bring Balloch Healthcare Investment Group, recently completed in the biomedical R & D outsourcing company Genscript Co., Ltd. (Jinsi Te Technology Co., Ltd.) of $ 15 million investment.
.
PISCATAWAY, 23rd Jun 2009: Genscript Co., Ltd. announced today: The company’s successfully from KPCB (KPCB) and Balloch China Healthcare Fund Investment Group (TBIG Healthcare) to obtained $ 15 million investment. As a leading international biotechnology company and biomedical research and development services outsourcing company, Genscript will increase R & D investment to further improve the level of bio-technology services, expansion of production capacity, optimization, and channels to enhance brand building, and make the company to become a pharmaceutical research and development outsourcing services leader in the field.
Genscript’s, co-founder and CEO Dr. Zhang Fang Liang said: “The KPCB and Balloch Healthcare Investment Group’s investment highly recognized our company’s business development vision with research and development of our technology through cost savings and shorten the drug development cycle, thus speeding up the drug development process in biological pharmaceutical R & D outsourcing company; also it confirmed our company’s industrial strategy, which is provide the high-quality, low cost, highly integrated power of pharmaceutical R & D services to pharmaceutical R & D industry to reform the existing process.
About Genscript
Genscript was founded in 2002, is a global scale and has a leading position in biotechnology and biomedical research and development services company and outsourcing company. The company co-founder Dr. Zhang Fang Liang, Dr. Wang Luquan and Miss Wang Ye have graduated from the internationally renowned institutions in their respective area of research has made remarkable achievements, they also has many years of experience in corporate services and management. Since its establishment, the company has been set up the biological research reagents, drug screening, drug targets and optimize antibody drug development of four service platforms. Genscript headquartered in New Jersey, Piscataway, also has branches in China, France and Japan, In the year of 2004, the company registered in Nanjing with Genscript (Nanjing) Biotechnology Co., Ltd., in 2009 the company established the Jin Sikang (Nanking) subsidiary.
About Balloch Healthcare Investment Group
Balloch Healthcare Investment Group (TBIG) is the subordinate branch of Balloch Group ( TBG ), jointly owned by Shipston Group Ltd. (SGL) TBG is a national and international company in China to provide marketing consulting services and commercial banking business, and in 2008 was voted the” Best Group of China” as a new investment bank. Shipsotn Group has been doing their business in China since 2005, the Vice-Chairman of the company, Hand Nordhoff who has been served as CEO of Gen-Probe in the United States. He is also the current leadership of TBIG and the consultant of TBG. Shipston Group founder Mr. Michael Dingman, was the CEO of Fisher Scientific International and he has been active in the healthcare industry for over 20 years.
Source:
http://www.genscript.com.cn/news_0623.html